Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 clinical pharmacology study of napabucasin in healthy volunteers
jRCT2080225351Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of napabucasin (4 arms), sponsored by Sumitomo Pharma. Primary endpoints: Tolerability and safety of single oral doses of napabucasin, Pharmacokinetics of napabucasin and 2 more. Started Aug 2020; status: completed.
02
Drugs
napabucasin
Beyond the preview
Go deeper on jRCT2080225351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225351.